{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:24:42Z","timestamp":1789680282884,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.yebeh.2023.109248","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T18:30:02Z","timestamp":1684521002000},"page":"109248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study"],"prefix":"10.1016","volume":"144","author":[{"given":"Jurriaan M.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita N.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2023.109248_b0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/NRL.0000000000000140","article-title":"Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives","volume":"22","author":"Penovich","year":"2017","journal-title":"Neurologist"},{"key":"10.1016\/j.yebeh.2023.109248_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109248_b0015","series-title":"Full prescribing information","article-title":"Epidiolex (cannabidiol oral solution)","author":"Greenwich Biosciences, Inc.","year":"2022"},{"key":"10.1016\/j.yebeh.2023.109248_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109248_b0025","series-title":"Full prescribing information","article-title":"VALTOCO (diazepam nasal spray)","author":"Neurelis, Inc.","year":"2023"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109248_b0030","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/epi.17041","article-title":"Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy","volume":"62","author":"Wheless","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109248_b0035","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/epi.17177","article-title":"Use of second doses of Valtoco\u00ae (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: results from a phase 3, open-label, repeat-dose safety study","volume":"63","author":"Sperling","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109248_b0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109248_b0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cn5000056","article-title":"Classics in chemical neuroscience: diazepam (valium)","volume":"5","author":"Calcaterra","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109248_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1313","article-title":"A comprehensive overview of the clinical pharmacokinetics of clobazam","volume":"59","author":"Tolbert","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109248_b0055","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109248_b0060","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109248_b0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109248_b0075","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109248_b0080","unstructured":"US Food and Drug Administration. Warning Letters and Test Results for Cannabidiol-Related Products; 2022. https:\/\/www.fda.gov\/news-events\/public-health-focus\/warning-letters-and-test-results-cannabidiol-related-products [accessed November 14, 2022]."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023001671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023001671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:51:24Z","timestamp":1761504684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023001671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"alternative-id":["S1525505023001671"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109248","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109248"}}